First in vivo fluorine-19 magnetic resonance imaging of the multiple sclerosis drug siponimod

Ludger Starke, Jason M. Millward, Christian Prinz, Fatima Sherazi, Helmar Waiczies, Christoph Lippert, Marc Nazaré, Friedemann Paul, Thoralf Niendorf, Sonia WaicziesTheranostics 2023 · DOI

Abstract

Theranostic imaging methods could greatly enhance our understanding of the distribution of CNS-acting drugs in individual patients. Fluorine-19 magnetic resonance imaging ($^{19}$F MRI) offers the opportunity to localize and quantify fluorinated drugs non-invasively, without modifications and without the application of ionizing or other harmful radiation. Here we investigated siponimod, a sphingosine 1-phosphate (S$_1$P) receptor antagonist indicated for secondary progressive multiple sclerosis (SPMS), to determine the feasibility of in vivo $^{19}$F MR imaging of a disease modifying drug. Methods: The $^{19}$F MR properties of siponimod were characterized using spectroscopic techniques. Four MRI methods were investigated to determine which was the most sensitive for $^{19}$F MR imaging of siponimod under biological conditions. We subsequently administered siponimod orally to 6 mice and acquired $^{19}$F MR spectra and images in vivo directly after administration, and in ex vivo tissues. Results: The $^{19}$F transverse relaxation time of siponimod was 381 ms when dissolved in dimethyl sulfoxide, and substantially reduced to 5 ms when combined with serum, and to 20 ms in ex vivo liver tissue. Ultrashort echo time (UTE) imaging was determined to be the most sensitive MRI technique for imaging siponimod in a biological context and was used to map the drug in vivo in the stomach and liver. Ex vivo images in the liver and brain showed an inhomogeneous distribution of siponimod in both organs. In the brain, siponimod accumulated predominantly in the cerebrum but not the cerebellum. No secondary $^{19}$F signals were detected from metabolites. From a translational perspective, we found that acquisitions done on a 3.0 T clinical MR scanner were 2.75 times more sensitive than acquisitions performed on a preclinical 9.4 T MR setup when taking changes in brain size across species into consideration and using equivalent relative spatial resolution. Conclusion: Siponimod can be imaged non-invasively using $^{19}$F UTE MRI in the form administered to MS patients, without modification. This study lays the groundwork for more extensive preclinical and clinical investigations. With the necessary technical development, $^{19}$F MRI has the potential to become a powerful theranostic tool for studying the time-course and distribution of CNS-acting drugs within the brain, especially during pathology.

Introduction

Understanding the distribution of drugs within the central nervous system (CNS) is a critical challenge in clinical medicine. For drugs like siponimod, which is effective for secondary progressive multiple sclerosis (SPMS), the ability to visualize accumulation in a specific patient's brain could significantly improve personalized treatment. Current tracking methods, such as PET or SPECT, require radioactive tracers that may alter the drug's behavior and expose patients to ionizing radiation.

Fluorine-19 ($^{19}$F) MRI is a promising alternative because many drugs already contain fluorine, and the human body has virtually no background fluorine signal. However, sensitivity remains a major hurdle: drugs exist at concentrations thousands of times lower than water, and their magnetic properties change drastically upon binding to proteins, often causing the signal to decay before it can be detected by standard MRI sequences.

Methods and Materials

The researchers combined spectroscopic characterization with pulse sequence optimization to address these challenges. They measured the longitudinal ($T_1$) and transverse ($T_2$) relaxation times of siponimod in various environments, including DMSO, human serum, and liver tissue. To identify the most sensitive imaging technique, they benchmarked four pulse sequences: RARE, FLASH, bSSFP, and Ultrashort Echo Time (UTE).

Spectroscopic characterization of siponimod signal fitting.

In vivo experiments were conducted on six C57BL/6 mice following oral administration of siponimod. Imaging was performed on a 9.4 T preclinical scanner using a cryogenically-cooled RF probe. Furthermore, the team modeled the translational potential by comparing the sensitivity of their preclinical setup against a clinical 3.0 T scanner, accounting for differences in voxel volume relative to brain size across species.

Results

A primary finding was the dramatic reduction in $T_2$ relaxation time in biological media. In DMSO, siponimod's $T_2$ was ~381 ms, but it plummeted to ~5 ms in serum. This rapid decay necessitates the use of UTE sequences, which begin data acquisition almost immediately after the RF pulse.

Impact of frequency correction on $^{19}$F MRI image quality.

The team successfully produced the first in vivo $^{19}$F images of siponimod in the stomach and liver of living mice. Ex vivo brain imaging revealed that the drug does not distribute evenly, accumulating significantly more in the cerebrum than in the cerebellum. No secondary $^{19}$F signals from metabolites were detected, suggesting the signal originates from the parent drug. Interestingly, the scaling analysis suggested that a clinical 3.0 T scanner could be 2.75 times more sensitive than a 9.4 T preclinical scanner for human applications due to the larger absolute voxel sizes possible in humans.

Discussion and Conclusion

This study demonstrates the feasibility of non-invasively imaging siponimod using $^{19}$F UTE MRI without chemical modification. While current in vivo brain imaging requires long acquisition times, the results provide a translational roadmap for clinical use. Future work will focus on accelerated imaging techniques and studying drug distribution in pathology models like Experimental Autoimmune Encephalomyelitis (EAE). Ultimately, $^{19}$F MRI has the potential to become a powerful theranostic tool for monitoring CNS-acting drugs in real-time.

Summary updated

Abstract

Theranostic imaging methods could greatly enhance our understanding of the distribution of CNS-acting drugs in individual patients. Fluorine-19 magnetic resonance imaging (<sup>19</sup>F MRI) offers the opportunity to localize and quantify fluorinated drugs non-invasively, without modifications and without the application of ionizing or other harmful radiation. Here we investigated siponimod, a sphingosine 1-phosphate (S<sub>1</sub>P) receptor antagonist indicated for secondary progressive multiple sclerosis (SPMS), to determine the feasibility of <i>in vivo</i> <sup>19</sup>F MR imaging of a disease modifying drug. <b>Methods:</b> The <sup>19</sup>F MR properties of siponimod were characterized using spectroscopic techniques. Four MRI methods were investigated to determine which was the most sensitive for <sup>19</sup>F MR imaging of siponimod under biological conditions. We subsequently administered siponimod orally to 6 mice and acquired <sup>19</sup>F MR spectra and images <i>in vivo</i> directly after administration, and in <i>ex vivo</i> tissues. <b>Results:</b> The <sup>19</sup>F transverse relaxation time of siponimod was 381 ms when dissolved in dimethyl sulfoxide, and substantially reduced to 5 ms when combined with serum, and to 20 ms in <i>ex vivo</i> liver tissue. Ultrashort echo time (UTE) imaging was determined to be the most sensitive MRI technique for imaging siponimod in a biological context and was used to map the drug <i>in vivo</i> in the stomach and liver. <i>Ex vivo</i> images in the liver and brain showed an inhomogeneous distribution of siponimod in both organs. In the brain, siponimod accumulated predominantly in the cerebrum but not the cerebellum. No secondary <sup>19</sup>F signals were detected from metabolites. From a translational perspective, we found that acquisitions done on a 3.0 T clinical MR scanner were 2.75 times more sensitive than acquisitions performed on a preclinical 9.4 T MR setup when taking changes in brain size across species into consideration and using equivalent relative spatial resolution. <b>Conclusion:</b> Siponimod can be imaged non-invasively using <sup>19</sup>F UTE MRI in the form administered to MS patients, without modification. This study lays the groundwork for more extensive preclinical and clinical investigations. With the necessary technical development, <sup>19</sup>F MRI has the potential to become a powerful theranostic tool for studying the time-course and distribution of CNS-acting drugs within the brain, especially during pathology.
BibTeX
@inproceedings{starke2023first,
  author = {Ludger Starke and Jason M. Millward and Christian Prinz and Fatima Sherazi and Helmar Waiczies and Christoph Lippert and Marc Nazaré and Friedemann Paul and Thoralf Niendorf and Sonia Waiczies},
  title = {{First <i>in vivo</i> fluorine-19 magnetic resonance imaging of the multiple sclerosis drug siponimod}},
  booktitle = {Theranostics},
  year = {2023},
  doi = {10.7150/thno.77041},
}
Figure